Development of liposome containing mycophenolic acid

Abstract

Mycophenolic acid (MPA) is an immunosuppressive drug, originally developed as a potential
antibiotic, antineoplastic and antipsoriatic drug. It is a potent and specific inhibitor of de novo purine synthesis
and blocks proliferation of both T and B lymphocytes. MPA has been approved for maintenance
immunosuppressive therapy of allogeneic graft rejection following solid organ transplantation. The aim
of this study was to develop the liposome containing MPA to enhance skin permeation after topical
administration. It was found that liposome of MPA could be prepared by modified ethanol injection
method using phopholipid from soybean (SPC), tween 80 and PEG as a wall material. The optimum ratio
was 84: 16: 1 (weight ratio) resulted in entrapment efficiency of 61.2% and the size ranging between
300 to 400 nm.